Streptococcus pneumoniae is the most common cause of community-acquired pneumonia,
meningitis, and bacteremia in children and adults. Invasive pneumococcal disease (IPD) …

Vaccine-induced antibodies may wane more quickly in persons living with human
immunodeficiency virus (HIV) than in healthy individuals. We reviewed the literature on …

An international panel of experts prepared an evidenced-based guideline for vaccination of
immunocompromised adults and children. These guidelines are intended for use by primary …

Background In South Africa, a 7-valent pneumococcal conjugate vaccine (PCV7) was
introduced in 2009 with a three-dose schedule for infants at 6, 14, and 36 weeks of age; a 13 …

SUMMARY On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein
conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer …

Background: Streptococcus pneumoniae is a leading and serious coinfection in adults with
human immunodeficiency virus (HIV) infection, particularly in Africa. Prevention of this …

Background: Pneumococcal conjugate vaccines (PCV) are emerging as one of the most
promising means to prevent pediatric disease. The 7-valent PCV (PCV-7) has been …

Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13)
against invasive pneumococcal disease (IPD) was based on a putative correlate of …

The global burden of disease due to Streptococcus pneumoniae remains high. The licensed
7-valent pneumococcal conjugate vaccine (7vCRM, Prevenar™/Prevnar™) has successfully …

The need for an effective vaccine to prevent the global spread of human immunodeficiency
virus type 1 (HIV-1) is well recognized. Passive immunization and challenge studies in non …